Manufacturing

Policymakers weigh new rules to ensure the safety and quality of drugs made with tiny particles.

A well-balanced guide to industrial bioseparations provides valuable information.

Brief pharmaceutical news items for November 2008.

Data capture needs to be fast and reliable...so which automatic identification technology is best?

The Indian government may soon monopolize its pharmaceutical industry to cut costs and improve healthcare, but the move is sounding off alarm bells with the companies whose drug products are under review.

The US Food and Drug Administration seeks to understand nanotechnology better and exercise appropriate oversight over products that incorporate it.

The authors evaluate the effect of various mill types on particle-size distribution, flowability, tabletability, and compactibility.

The authors examine the effectiveness of an excipient comprised of mannitol, polyvinyl acetate, and crospovidone using model actives loperamide hydrogen chloride and caffeine.

Pharma companies could benefit from the lessons learned in this fall's financial crisis.

Editors' Picks of Pharmaceutical Science & Technology Innovations

Production problems come in all shapes, sizes, and ... species.

Pharmaceutical Technology will feature video coverage of AAPS this month.

Molecules called "chaperones" facilitate correct protein folding.

The authors explain the factors that can cause a failure in a bubble-point integrity test and what to consider when a product-specific bubble point must be defined.

The author discusses the key issues to consider when using isolators such as containment, protection of personnel, the efficiency of biodecontamination cycles, sterility assurance levels, barriers and their integrity, and environmental impact.

The authors describe a novel approach for the integrity testing of large sterile filter systems such as multiround housings and describe a multipoint diffusion test capable of detecting minor failures.

Proper selection of normal flow filters leads to increased process efficiency from early phase product development through to full-scale biopharmaceutical production.

The authors present an aseptic-filling process for freeze-dried liquids using the closed-vial technology.

A comparison of conventional cleanrooms, restricted access barrier systems, and isolators, shows the benefits of using isolators in high-potency drug manufacturing.

I confess I am no financial expert. My knowledge about the current credit crisis can be summed up in six words: 'debt is bad; cash is good', which was pretty much the limit of my understanding about money before it all began.

The author examines re-use of hydrophilic- or hydrophobic-membrane sterilizing-grade filters in liquid sterilizing applications.

Many industries, from aerospace to medical devices, conduct cleaning procedures.

There are many challenges upstream and downstream in manufacturing a biotech drug.

FDA advocates building quality into a product through PAT.

Many compounds fail in preclinical development because of safety-related problems, but identifying 'predictable' safety or toxicity liabilities earlier in the process could lead to improved design and selection of compounds that are more likely to be approved.